Panax Ginseng Components and the Pathogenesis of Alzheimer's Disease (Review)

Overview

Journal Mol Med Rep

Specialty Molecular Biology

Date 2019 Mar 1

PMID 30816465

Citations 42

Authors

Mayya Petrovna Razgonova

Valery Vyacheslavovich Veselov

Alexander Mikhailovich Zakharenko

Kirill Sergeyevich Golokhvast

Alexander Evgenyevich Nosyrev

Giancarlo Cravotto

Aristidis Tsatsakis

Demetrios A Spandidos

Affiliations

Soon will be listed here.

Abstract

Ginseng is one of the main representatives of traditional Chinese medicine and presents a wide range of pharmacological actions. Ginsenosides are the main class of active compounds found in ginseng. They demonstrate unique biological activity and medicinal value, namely anti-tumour, anti‑inflammatory and antioxidant properties, as well as anti-apoptotic properties. Increasing levels of stress in life are responsible for the increased incidence of nervous system diseases. Neurological diseases create a huge burden on the lives and health of individuals. In recent years, studies have indicated that ginsenosides play a pronounced positive role in the prevention and treatment of neurological diseases. Nevertheless, research is still at an early stage of development, and the complex mechanisms of action involved remain largely unknown. This review aimed to shed light into what is currently known about the mechanisms of action of ginsenosides in relation to Alzheimer's disease. Scientific material and theoretical bases for the treatment of nervous system diseases with purified Panax ginseng extracts are also discussed.

Citing Articles

and formula protects brain function in Alzheimer's disease.

Liu J, Wei F, Wang Y, Liu J, Xu B, Ma S Front Pharmacol. 2025; 16:1461177.

PMID: 40051562 PMC: 11882532. DOI: 10.3389/fphar.2025.1461177.

Phytotherapy in Alzheimer's Disease-A Narrative Review.

Piekarz J, Picheta N, Burdan O, Kurek M, Chroscinska-Krawczyk M Biomedicines. 2024; 12(8).

PMID: 39200276 PMC: 11351709. DOI: 10.3390/biomedicines12081812.

and pharmacokinetic studies of glucomoringin from root for Alzheimer's disease like pathology.

Manogna C, Margesan T Future Sci OA. 2024; 10(1):2340280.

PMID: 38817392 PMC: 11137837. DOI: 10.2144/fsoa-2023-0255.

Effects of saponins Rb and Re in combined intervention on immune system of aging model.

Shi M, Ma J, Jin S, Wang T, Sui Y, Chen L Front Mol Biosci. 2024; 11:1392868.

PMID: 38606290 PMC: 11007219. DOI: 10.3389/fmolb.2024.1392868.

Ginsenosides Decrease β-Amyloid Production via Potentiating Capacitative Calcium Entry.

Cho Y, Park J, Lee J, Chung S Biomol Ther (Seoul). 2024; 32(3):301-308.

PMID: 38586949 PMC: 11063476. DOI: 10.4062/biomolther.2023.172.

References

Choi R, Roy A, Jin Jung H, Ali M, Min B, Park C . BACE1 molecular docking and anti-Alzheimer's disease activities of ginsenosides. J Ethnopharmacol. 2016; 190:219-30. DOI: 10.1016/j.jep.2016.06.013. View

Raschetti R, Albanese E, Vanacore N, Maggini M . Cholinesterase inhibitors in mild cognitive impairment: a systematic review of randomised trials. PLoS Med. 2007; 4(11):e338. PMC: 2082649. DOI: 10.1371/journal.pmed.0040338. View

Huang X, Ding H, Lu J, Tang Y, Deng B, Deng C . Effects of the Combination of the Main Active Components of Astragalus and Panax notoginseng on Inflammation and Apoptosis of Nerve Cell after Cerebral Ischemia-Reperfusion. Am J Chin Med. 2015; 43(7):1419-38. DOI: 10.1142/S0192415X15500809. View

Yang J, Wang Z, Cai H, Yuan L, Hu M, Wu M . Sex Differences in Neuropathology and Cognitive Behavior in APP/PS1/tau Triple-Transgenic Mouse Model of Alzheimer's Disease. Neurosci Bull. 2018; 34(5):736-746. PMC: 6129237. DOI: 10.1007/s12264-018-0268-9. View

Tohda C, Matsumoto N, Zou K, Meselhy M, Komatsu K . Abeta(25-35)-induced memory impairment, axonal atrophy, and synaptic loss are ameliorated by M1, A metabolite of protopanaxadiol-type saponins. Neuropsychopharmacology. 2004; 29(5):860-8. DOI: 10.1038/sj.npp.1300388. View

Li X, Liu Y, Zhang X, Yuan H, Quan Q . [Effect of ginsenoside Rg1 on expressions of phosphory protein tau and N-methyl-D-aspartate receptor subunits NR1 and NR2B in rat brain slice model of Alzheimer's disease]. Zhongguo Zhong Yao Za Zhi. 2011; 35(24):3339-43. View

Wang X, Zeng C, Lin J, Chen T, Zhao T, Jia Z . Metabonomics approach to assessing the modulatory effects of St John's wort, ginsenosides, and clomipramine in experimental depression. J Proteome Res. 2012; 11(12):6223-30. DOI: 10.1021/pr300891v. View

Zetterberg H, Alexander D, Spandidos D, Blennow K . Additional evidence for antagonistic pleiotropic effects of APOE. Alzheimers Dement. 2009; 5(1):75. DOI: 10.1016/j.jalz.2008.10.005. View

Quan Q, Wang J, Li X, Wang Y . Ginsenoside Rg1 decreases Aβ(1-42) level by upregulating PPARγ and IDE expression in the hippocampus of a rat model of Alzheimer's disease. PLoS One. 2013; 8(3):e59155. PMC: 3592813. DOI: 10.1371/journal.pone.0059155. View

10.

Wang Y, Kan H, Yin Y, Wu W, Hu W, Wang M . Protective effects of ginsenoside Rg1 on chronic restraint stress induced learning and memory impairments in male mice. Pharmacol Biochem Behav. 2014; 120:73-81. DOI: 10.1016/j.pbb.2014.02.012. View

11.

Heo J, Park M, Lee J . Effect of Korean Red Ginseng on Cognitive Function and Quantitative EEG in Patients with Alzheimer's Disease: A Preliminary Study. J Altern Complement Med. 2016; 22(4):280-5. DOI: 10.1089/acm.2015.0265. View

12.

Chen Y, Sun J, Fang L, Liu M, Peng S, Liao H . Tacrine-ferulic acid-nitric oxide (NO) donor trihybrids as potent, multifunctional acetyl- and butyrylcholinesterase inhibitors. J Med Chem. 2012; 55(9):4309-21. DOI: 10.1021/jm300106z. View

13.

Choi D, Rothman S . The role of glutamate neurotoxicity in hypoxic-ischemic neuronal death. Annu Rev Neurosci. 1990; 13:171-82. DOI: 10.1146/annurev.ne.13.030190.001131. View

14.

Roberson E, Halabisky B, Yoo J, Yao J, Chin J, Yan F . Amyloid-β/Fyn-induced synaptic, network, and cognitive impairments depend on tau levels in multiple mouse models of Alzheimer's disease. J Neurosci. 2011; 31(2):700-11. PMC: 3325794. DOI: 10.1523/JNEUROSCI.4152-10.2011. View

15.

Kim S, Rhim H . Ginsenosides inhibit NMDA receptor-mediated epileptic discharges in cultured hippocampal neurons. Arch Pharm Res. 2004; 27(5):524-30. DOI: 10.1007/BF02980126. View

16.

Yan S, Li Z, Li H, Arancio O, Zhang W . Notoginsenoside R1 increases neuronal excitability and ameliorates synaptic and memory dysfunction following amyloid elevation. Sci Rep. 2014; 4:6352. PMC: 4161968. DOI: 10.1038/srep06352. View

17.

Quan Q, Li X, Yuan H, Wang Y, Liu W . Ginsenoside Rg1 inhibits high-voltage-activated calcium channel currents in hippocampal neurons of beta-amyloid peptide-exposed rat brain slices. Chin J Integr Med. 2016; . DOI: 10.1007/s11655-015-2301-4. View

18.

Heo J, Lee S, Chu K, Oh M, Park H, Shim J . An open-label trial of Korean red ginseng as an adjuvant treatment for cognitive impairment in patients with Alzheimer's disease. Eur J Neurol. 2008; 15(8):865-8. DOI: 10.1111/j.1468-1331.2008.02157.x. View

19.

Geula C, Mesulam M . Cholinesterases and the pathology of Alzheimer disease. Alzheimer Dis Assoc Disord. 1995; 9 Suppl 2:23-8. DOI: 10.1097/00002093-199501002-00005. View

20.

Li J, Liu Y, Li W, Wang Z, Guo P, Li L . Metabolic profiling of the effects of ginsenoside Re in an Alzheimer's disease mouse model. Behav Brain Res. 2017; 337:160-172. DOI: 10.1016/j.bbr.2017.09.027. View